HIV-1: cobas HIV-1 is built upon the dual-target assay design from Roche. The ability to consolidate and automate a wider array of testing on a single platform helps to increase operational efficiency, maximise laboratory space and minimise capital investment. Open channel assays may include IVD assays, research testing, as well as routine lab developed tests (LDTs). The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform. Roche anticipates tests to be available beyond CE markets in additional countries in 2022.Ībout the cobas omni Utility Channel on the cobas 5800 System Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022. The cobas 5800 System will offer the same menu as the cobas 68 Systems. The cobas 5800 System, a compact new addition to the Roche Diagnostics Molecular Work Area, is built upon the innovation of the cobas® 68 Systems, making molecular testing accessible to more patients around the world. "We are pleased that we can increase access to accurate, timely and reliable diagnostics with our first tests on the cobas 5800 System to patients and their healthcare teams to meet evolving testing demands." "Roche offers a comprehensive portfolio of infectious disease tests along the continuum of care, enabling laboratories to provide the right information, from screening and diagnosis, for patient management and treatment monitoring," said Cindy Perettie, Head of the Molecular Lab Customer Area, Roche Diagnostics. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.
15, 2021 /PRNewswire/ - Roche (SIX: RO, ROG OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas® HIV-1, cobas® HBV, cobas® HCV, cobas® HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit.
0 kommentar(er)
